Also, there was no significant difference between alirocumab and evolocumab in causing cataracts (OR 1.95, 95% CI 0.69â5.49, p=0.208 and OR 1.02, 95% CI.
1256
Lower targets for hypertension? / Cholesterol-lowering therapy for primary and secondary prevention
showed a dose-response trend between achieved SBP and event rate for MACCE (P
